BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aherfi S, Pradines B, Devaux C, Honore S, Colson P, Scola B, Raoult D. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol 2021;16:1341-70. [PMID: 34755538 DOI: 10.2217/fmb-2021-0019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Beltz LA. COVID-19. Pathogenic Coronaviruses of Humans and Animals 2023. [DOI: 10.1016/b978-0-323-98809-4.00013-9] [Reference Citation Analysis]
2 Yu H, Li L, Huffman A, Beverley J, Hur J, Merrell E, Huang HH, Wang Y, Liu Y, Ong E, Cheng L, Zeng T, Zhang J, Li P, Liu Z, Wang Z, Zhang X, Ye X, Handelman SK, Sexton J, Eaton K, Higgins G, Omenn GS, Athey B, Smith B, Chen L, He Y. A new framework for host-pathogen interaction research. Front Immunol 2022;13:1066733. [PMID: 36591248 DOI: 10.3389/fimmu.2022.1066733] [Reference Citation Analysis]
3 Govender K, Chuturgoon A. An Overview of Repurposed Drugs for Potential COVID-19 Treatment. Antibiotics (Basel) 2022;11. [PMID: 36551336 DOI: 10.3390/antibiotics11121678] [Reference Citation Analysis]
4 Agrawal PK, Agrawal C, Blunden G. Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment? Molecules 2022;27:3828. [PMID: 35744958 DOI: 10.3390/molecules27123828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Puhl AC, Gomes GF, Damasceno S, Godoy AS, Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, Monakhova N, Riabova O, Lane TR, Makarov V, Veras FP, Batah SS, Fabro AT, Oliva G, Cunha FQ, Alves-Filho JC, Cunha TM, Ekins S. Pyronaridine Protects against SARS-CoV-2 Infection in Mouse. ACS Infect Dis 2022;8:1147-60. [PMID: 35609344 DOI: 10.1021/acsinfecdis.2c00091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lagier JC, Million M, Cortaredona S, Delorme L, Colson P, Fournier PE, Brouqui P, Raoult D, Parola P; IHU Task Force. Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Ther Clin Risk Manag 2022;18:603-17. [PMID: 35669696 DOI: 10.2147/TCRM.S364022] [Reference Citation Analysis]
7 LoMascolo NJ, Cruz-Pulido YE, Mounce BC. Bisacodyl Limits Chikungunya Virus Replication In Vitro and Is Broadly Antiviral. Antimicrob Agents Chemother 2022;:e0029222. [PMID: 35652314 DOI: 10.1128/aac.00292-22] [Reference Citation Analysis]
8 Khalil TE, Elbadawy HA, Attia AA, El-Sayed DS. Synthesis, spectroscopic, and computational studies on molecular charge-transfer complex of 2-((2-hydroxybenzylidene) amino)-2-(hydroxymethyl) propane-1, 3-diol with chloranilic acid: Potential antiviral activity simulation of CT-complex against SARS-CoV-2. J Mol Struct 2022;1251:132010. [PMID: 34866653 DOI: 10.1016/j.molstruc.2021.132010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Jiang H, Yang P, Zhang J. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone. Front Chem 2022;10:822785. [DOI: 10.3389/fchem.2022.822785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Chaplin S. Antibody therapies to prevent and treat COVID ‐19. Prescriber 2022;33:23-28. [DOI: 10.1002/psb.1969] [Reference Citation Analysis]